Regardless, in grafted TNBC PDX tumors, we observed high PD‐L1 in IHC studies after DR5 agonist treatments and their co‐targeting (PD‐L1 + DR5) significantly improved immune effector function and anti‐tumor efficacy. This evidence concerns the gene CD274 and neoplasm.